JP2024534496A5 - - Google Patents
Info
- Publication number
- JP2024534496A5 JP2024534496A5 JP2024517415A JP2024517415A JP2024534496A5 JP 2024534496 A5 JP2024534496 A5 JP 2024534496A5 JP 2024517415 A JP2024517415 A JP 2024517415A JP 2024517415 A JP2024517415 A JP 2024517415A JP 2024534496 A5 JP2024534496 A5 JP 2024534496A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- combinations
- mrna
- fusion protein
- grna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246689P | 2021-09-21 | 2021-09-21 | |
| US63/246,689 | 2021-09-21 | ||
| US202263352530P | 2022-06-15 | 2022-06-15 | |
| US63/352,530 | 2022-06-15 | ||
| PCT/US2022/076723 WO2023049707A1 (en) | 2021-09-21 | 2022-09-20 | Mrna regulon therapy for the treatment of haploinsufficiency disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534496A JP2024534496A (ja) | 2024-09-20 |
| JP2024534496A5 true JP2024534496A5 (enExample) | 2025-09-10 |
Family
ID=85719677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517415A Pending JP2024534496A (ja) | 2021-09-21 | 2022-09-20 | ハプロ不全障害の処置のためのｍＲＮＡレギュロン療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250135035A1 (enExample) |
| EP (1) | EP4404953A4 (enExample) |
| JP (1) | JP2024534496A (enExample) |
| KR (1) | KR20240099184A9 (enExample) |
| AU (1) | AU2022349620A1 (enExample) |
| CA (1) | CA3232214A1 (enExample) |
| MX (1) | MX2024003412A (enExample) |
| WO (1) | WO2023049707A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4514955A1 (en) * | 2022-04-29 | 2025-03-05 | The Johns Hopkins University | Systems for enhancing mrna expression and uses thereof |
| WO2025165891A1 (en) | 2024-01-29 | 2025-08-07 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015221026A (ja) * | 2014-05-23 | 2015-12-10 | 公立大学法人名古屋市立大学 | 人工合成ｍＲＮＡの翻訳効率化方法 |
| US20180312873A1 (en) * | 2015-10-20 | 2018-11-01 | 10X Genomics, Inc. | Method and systems for high throughput single cell genetic manipulation |
| EP3579858A4 (en) * | 2017-02-07 | 2020-12-23 | The Regents of The University of California | GENE THERAPY AGAINST HAPLOINSUFFICIENCY |
| KR20260009385A (ko) * | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| EP4013873A1 (en) * | 2019-08-16 | 2022-06-22 | Massachusetts Institute Of Technology | Targeted trans-splicing using crispr/cas13 |
| US20230078498A1 (en) * | 2020-02-07 | 2023-03-16 | University Of Rochester | Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis |
-
2022
- 2022-09-20 KR KR1020247012661A patent/KR20240099184A9/ko active Pending
- 2022-09-20 EP EP22873808.4A patent/EP4404953A4/en active Pending
- 2022-09-20 US US18/693,636 patent/US20250135035A1/en active Pending
- 2022-09-20 AU AU2022349620A patent/AU2022349620A1/en active Pending
- 2022-09-20 CA CA3232214A patent/CA3232214A1/en active Pending
- 2022-09-20 MX MX2024003412A patent/MX2024003412A/es unknown
- 2022-09-20 WO PCT/US2022/076723 patent/WO2023049707A1/en not_active Ceased
- 2022-09-20 JP JP2024517415A patent/JP2024534496A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2572811T3 (es) | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos | |
| JP2022502044A5 (enExample) | ||
| EP3263122B1 (en) | Peptide for preventing hearing loss, and composition comprising same | |
| JP5784877B2 (ja) | 喘息治療のためのフマル酸誘導体含有薬剤 | |
| JP2002523028A (ja) | 安定な低酸素誘導性因子１αおよび使用方法 | |
| JP2005506316A (ja) | 活性型ＴＧＦ−βが濃縮されたタンパク質画分を得る方法、タンパク質画分および治療的適用 | |
| CN102245629B (zh) | 修饰的淀粉状蛋白β肽 | |
| JP2022502392A (ja) | 経口剤形の製造方法 | |
| JPS5837285B2 (ja) | チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ | |
| CN100413888C (zh) | 可溶性多肽 | |
| JP2001510981A (ja) | Ｉｘ型コラーゲンおよびキメラ | |
| US8071716B2 (en) | Thymus-specific protein | |
| CN117070534A (zh) | 一种预防和治疗动物传染性腹膜炎的药物组合物 | |
| JPH05255096A (ja) | 初老期痴呆または老年痴呆の治療用医薬組成物 | |
| JPH10501888A (ja) | 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン | |
| CN118252913B (zh) | 多肽偶联物及其在射血分数保留的心衰中的应用 | |
| JP5916051B2 (ja) | 抗炎症剤および抗炎症剤の製造方法 | |
| RS49733B (sr) | Soli bpc peptida sa organo- zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena | |
| US11084879B2 (en) | Compositions and methods for treating pancreatitis and pain with death receptor agonists | |
| JP2025500508A5 (enExample) | ||
| EP2954904B9 (en) | Use of long-acting human recombinant soluble tumour necrosis factor receptor in the preparation of drugs for preventing and treating chronic liver diseases and severe liver damage | |
| JP5439007B2 (ja) | 血管内皮細胞増殖因子阻害剤及び抗癌剤 | |
| JP3031693B2 (ja) | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 | |
| EP4648789A1 (en) | Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction | |
| WO1998043665A1 (fr) | Agent preventif et/ou therapeutique pour les maladies des reins |